SCOHIA initiates a phase 2 proof of concept study on
an enteropeptidase inhibitor (SCO-792) for diabetic kidney disease

Today, SCOHIA PHARMA, Inc., announced that an enteropeptidase inhibitor (SCO-792) has progressed into phase 2 proof of concept study in patients with diabetic kidney disease.

This is a randomized, multicenter, double-blind, placebo-controlled, parallel-group study conducted to evaluate the safety and efficacy of SCO-792 in approximately 75 diabetic kidney disease patients in Australia and New Zealand.

For more information about the study, visit the following website:
https://www.clinicaltrials.jp/cti-user/trial/Search.jsp
(Please search by JapicCTI-205109)

Regarding SCO-792, we have already initiated the phase 2 proof of concept study in type 2 diabetes mellitus patients with obesity in Australia and New Zealand from November 2019.

[About enteropeptidase inhibitor SCO-792]
Enteropeptidase is a serine protease localized at the brush border of the duodenal and jejunal mucosa. It plays a key role in the digestion of proteins to amino acids in mammals. SCOHIA researchers and collaborators identified SCO-792, a new potent orally available enteropeptidase inhibitor, and revealed its therapeutic benefits in improving diabetes and obesity through preclinical studies. Furthermore, enteropeptidase inhibition improves kidney function in preclinical diabetic and non-diabetic kidney disease models. For detailed information about SCO-792, please visit https://www.scohia.com/eng/sys/pipeline/sco-792/.
SCOHIA PHARMA, Inc., is a drug discovery bioventure focusing on lifestyle-related diseases such as cardiovascular, metabolic, and renal diseases. Our R&D team has a rich pipeline and track record in each stage of drug development, including compound discovery, drug evaluation, and clinical development, which makes us special. For detailed information about SCOHIA PHARMA, Inc., please visit https://www.scohia.com/eng/.